Celera and LabCorp® Announce Agreement to Commercialize Breast Cancer Testing Essays
News Apr 25, 2007
Celera, an Applera Corporation business, and Laboratory Corporation of America® Holdings (LabCorp®) announced that they have signed an agreement granting LabCorp a license to Celera's breast cancer metastasis and estrogen/progesterone receptor discoveries.
The license agreement allows LabCorp to select from among Celera's genomic findings to develop and commercialize two molecular oncology laboratory service tests.
LabCorp plans to offer one test to help predict the risk of metastasis in early stage breast cancer patients, and a second test to provide a molecular assessment of hormonal receptor status, which is used to select women for endocrine therapy.
The tests that LabCorp plans to offer based on Celera's findings may provide information that is distinct from that predicted by routine clinical assessment tools, such as tumor grade, as well as quantify risk for metastasis for variable time periods rather than only categorically for five or 10 years.
Many of the discoveries licensed to LabCorp under this agreement are involved in the p53 tumor suppressor signaling pathways and are implicated in cancer proliferation.
Under the terms of the agreement, LabCorp will pay Celera an up-front license fee and royalties on net sales of laboratory service tests performed by LabCorp that incorporate Celera's discoveries. Further financial details were not disclosed.
"This license agreement with Celera strategically complements our innovative and extensive pipeline of diagnostic services and reinforces our strong commitment to genetic and molecular oncology testing," said Myla P. Lai-Goldman, M.D., Executive Vice President, Chief Scientific Officer and Medical Director of LabCorp.
"Applying Celera's findings in breast cancer to the development of new tests supports our ever-growing menu of esoteric and genomic tests, and underscores our commitment to bring relevant clinical tests to market," Lai-Goldman further said.
"We are pleased to have entered into this agreement with LabCorp, which has a track record of introducing new testing services that improve patient management," said Kathy Ordonez, President of Celera.
"LabCorp shares our belief that Celera's breast cancer discoveries could have a beneficial effect on hundreds of thousands of women living with the uncertainty of breast cancer recurrence," Ordonez added.